2025
Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer
Huang S, Westvold S, Soulos P, Fan J, Winer E, Zhan H, Lustberg M, Lewin J, Robinson T, Dinan M. Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer. JAMA Network Open 2025, 8: e255322. PMID: 40232715, DOI: 10.1001/jamanetworkopen.2025.5322.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityBreast cancer mortalityBreast cancer diagnosisCancer-specific mortalityCancer mortalityCancer diagnosisScreening mammographyHazard of breast cancer-specific deathFee-for-service Medicare Parts AAssociated with reduced breast cancer mortalityLower breast cancer mortalityHazard of breast cancer-specific mortalityBreast cancerImprove breast cancer outcomesScreen-detected breast cancerCohort studyBreast cancer-specific deathStudy of older womenBreast cancer outcomesFee-for-serviceDetection of breast cancerMedicare Part ALater-stage diseaseCox proportional hazards modelsAssociated with early stagesGenomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies
Janjigian Y, Cecchini M, Shitara K, Enzinger P, Wainberg Z, Chau I, Satoh T, Lee J, Nebozhyn M, Loboda A, Kobie J, Vajdi A, Shih C, Cristescu R, Cao Z. Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies. JCO Precision Oncology 2025, 9: e2400456. PMID: 40117530, PMCID: PMC11949223, DOI: 10.1200/po-24-00456.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedExome SequencingFemaleGenomicsHumansMaleMicrosatellite InstabilityMiddle AgedNeoplasm StagingStomach NeoplasmsConceptsTumor mutational burdenHomologous recombination deficiencyMicrosatellite instability-highGenomic characteristicsChromosomal instabilityKEYNOTE-062Late-stage GCKEYNOTE-059KEYNOTE-061Molecular subtypesAsian originWhole-exome sequencingGastric cancerSubtype prevalenceEpstein-Barr virus-positiveHomologous recombination deficiency scoresPretreatment tumor samplesWES dataGene expression signaturesCancer Genome AtlasMicrosatellite instability-high subtypeRNA sequencingGenomic landscapeEarly-stage GCGenomic alterationsComparison of prognostic accuracy of HCC staging systems in patients undergoing TACE
Kasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE. Clinical Imaging 2025, 120: 110438. PMID: 40049074, DOI: 10.1016/j.clinimag.2025.110438.Peer-Reviewed Original ResearchConceptsOverall survival of patientsBCLC staging systemTransarterial chemoembolizationOverall survivalStaging systemHepatocellular carcinomaStaging systems of hepatocellular carcinomaHepatocellular carcinoma staging systemsRetrospective single center studyKaplan Meier survival analysisInternational Staging SystemSingle center studyLog-rank testTertiary care centerPredicting overall survivalMeier survival analysisConsecutive patientsPrognostic stratificationStudy endpointPrognostic accuracyCenter studyPrognostic powerStratify outcomesMultivariate analysisPatientsRacial and ethnic disparities in conversion to mastectomy following lumpectomy
Khubchandani J, KC M, Dey P, Proussaloglou E, Valero M, Berger E, Park T, Gross C, Butler P, Fayanju O, Winer E, Golshan M, Greenup R. Racial and ethnic disparities in conversion to mastectomy following lumpectomy. Breast Cancer Research And Treatment 2025, 211: 99-110. PMID: 39937397, DOI: 10.1007/s10549-025-07625-6.Peer-Reviewed Original ResearchConceptsConversion to mastectomyNeoadjuvant chemotherapyBreast conservationStage 0-III breast cancerWhite womenBreast cancerBlack womenBreast cancer careNational Cancer DatabaseMultivariate logistic regression modelEvaluate contemporary trendsLogistic regression modelsCancer careImprove disparitiesEthnic disparitiesDiagnosis yearInitial lumpectomySocio-demographicCancer DatabaseClinical factorsMastectomyLumpectomySurgeryResultsThe studyTreatment sequenceProgressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes
Xu W, Birch G, Meliki A, Moritz V, Bharadwaj M, Schindler N, Labaki C, Saliby R, Dinh K, Horst J, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee G, Hurwitz M, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open 2025, 10: 104105. PMID: 39813824, PMCID: PMC11783098, DOI: 10.1016/j.esmoop.2024.104105.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellFemaleHumansKidney NeoplasmsKiller Cells, NaturalMaleMiddle AgedNeoplasm StagingConceptsClear-cell renal cell carcinomaAdvanced clear-cell renal cell carcinomaNK cell phenotypeNK cell functionNK cellsRenal cell carcinomaClinical outcomesCell carcinomaCell phenotypeRestoration of NK cell functionNormal kidneyNatural killer (NK) cellsMarkers of tissue residencyNatural killer cell dysfunctionAssociated with worse overall survivalClear-cell renal cell carcinoma patientsLocalized clear-cell renal cell carcinomaTumor-infiltrating NK cellsAnalyzed single-cell RNA sequencing dataAssociated with worse survivalExpression of cytotoxic genesPaired normal kidneyLocal tumor extensionNK cell subsetsPrimary tumor specimensOutcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
DeMichele A, Dueck A, Hlauschek D, Martin M, Burstein H, Pfeiler G, Zdenkowski N, Wolff A, Bellet-Ezquerra M, Winer E, Balic M, Miller K, Colleoni M, Lake D, Rubovsky G, Cameron D, Balko J, Singer C, Nowecki Z, Iwata H, Wolmark N, Parraga K, Rugo H, Steger G, Traina T, Werutsky G, Czajkowska D, Metzger O, El-Abed S, Theall K, Lu R, O’Brien P, Fesl C, Mayer E, Gnant M. Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]). Breast Cancer Research 2025, 27: 12. PMID: 39849600, PMCID: PMC11761723, DOI: 10.1186/s13058-024-01941-3.Peer-Reviewed Original ResearchConceptsLocoregional relapse-free survivalStandard adjuvant endocrine therapyYears of palbociclibAdjuvant endocrine therapyEndocrine therapyOverall survivalStage IIAPALLAS trialBreast cancerFollow-upBreast cancer-free survivalReducing breast cancer recurrenceStage IIA patientsHigher stage diseaseHormone-receptor-positiveRelapse-free survivalStage IIA diseaseYears of follow-upCancer-free survivalMedian follow-upPhase III trialsEarly breast cancerBreast cancer recurrenceBreast Cancer Study GroupNegative breast cancer
2024
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
Matei D, Enserro D, Randall M, Mutch D, Small W, DiSilvestro P, Spirtos N, O’Malley D, Cantuaria G, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland F, Warshal D, Bonebrake A, Tewari K, Tan A, Powell M, Walker J, Santin A, Kim J, Miller D. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. Journal Of Clinical Oncology 2024, 43: 1055-1060. PMID: 39700442, PMCID: PMC11908887, DOI: 10.1200/jco.24.01121.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalRandomized phase III trialOverall survivalC-RTFederation of Gynecology and Obstetrics (FIGOInternational Federation of Gynecology and Obstetrics (FIGOFollow-upIncreased recurrence-free survivalLocally advanced endometrial cancerLocally advanced endometrial carcinomaRate of local recurrenceLymph-vascular space invasionLong-term follow-upGross residual diseaseStratified hazard ratioProbability of OSAdvanced endometrial cancerMedian follow-upAdvanced endometrial carcinomaKaplan-Meier methodPhase III trialsBody mass indexMedian OSOS benefitPositive cytologyDNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance
Conway K, Edmiston S, Vondras A, Reiner A, Corcoran D, Shen R, Parrish E, Hao H, Lin L, Kenney J, Ilelaboye G, Kostrzewa C, Kuan P, Busam K, Lezcano C, Lee T, Hernando E, Googe P, Ollila D, Moschos S, Gorlov I, Amos C, Ernstoff M, Cust A, Wilmott J, Scolyer R, Mann G, Vergara I, Ko J, Rees J, Yan S, Nagore E, Bosenberg M, Rothberg B, Osman I, Lee J, Saenger Y, Bogner P, Thompson C, Gerstenblith M, Holmen S, Funchain P, Brunsgaard E, Depcik-Smith N, Luo L, Boyce T, Orlow I, Begg C, Berwick M, Thomas N, Berwick M, Luo L, Boyce T, Reynolds A, Wiggins C, Thomas N, Conway K, Edmiston S, Ollila D, Hao H, Parrish E, Googe P, Moschos S, Corcoran D, Vondras A, Tsai Y, Lin L, Shen R, Begg C, Arora A, Seshan V, Reiner A, Kostrzewa C, Busam K, Orlow I, Lezcano C, Kenney J, Sadeghi K, O'Connell K, Ilelaboye G, Parmar H, Leong S, Corrales S, Scolyer R, Cust A, Wilmott J, Mann G, Shang P, Burke H, Ferguson P, Jakrot V, Lee T, Hernando E, Osman I, Hanniford D, Argibay D, Moran U, Heguy A, Ramaswami S, Amos C, Gorlov I, Zhu D, Ernstoff M, Bogner P, Lee J, Rees J, Yan S, Gerstenblith M, Thompson C, Ko J, Funchain P, Ngo P, Bosenberg M, Gould Rothberg B, Panse G, Saenger Y, Fullerton B, Holmen S, Colman H, Brunsgaard E, Wada D, Nagore E, Manrique-Silva E, Requena C, Traves V, Millan-Esteban D, Rainka M. DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO Precision Oncology 2024, 8: e2400375. PMID: 39509669, PMCID: PMC11737429, DOI: 10.1200/po-24-00375.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerCpG island methylator phenotypePrimary melanomaBreslow thicknessMethylation classClinicopathological characteristicsN stageRisk of melanoma-related deathLow methylationStage IIRetrospective case-control studyCutaneous primary melanomaHigher AJCC stagePrimary cutaneous melanomaHigher N stageMelanoma-related deathDNA methylation classDied of melanomaMitotic indexCase-control studyIII patientsClinicopathological factorsCpG island hypermethylationPrognostic significanceAJCC stageManagement of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Zilli T, Agarwal N, Antonarakis E, Aparicio A, Armstrong A, Bastos D, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon M, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Clarke C, Clarke N, de Bono J, De Santis M, Duran I, Efstathiou E, Ekeke O, El Nahas T, Emmett L, Fanti S, Fatiregun O, Feng F, Fong P, Fonteyne V, Fossati N, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman M, Hope T, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Joshua A, Kanesvaran R, Keizman D, Khauli R, Kramer G, Loeb S, Mahal B, Maluf F, Mateo J, Matheson D, Matikainen M, McDermott R, McKay R, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Mutambirwa S, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Renard-Penna R, Ryan C, Saad F, Sade J, Sandhu S, Sartor O, Schaeffer E, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Suzuki H, Taplin M, Thellenberg-Karlsson C, Tilki D, Türkeri L, Uemura H, Ürün Y, Vale C, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). European Urology 2024, 87: 157-216. PMID: 39394013, DOI: 10.1016/j.eururo.2024.09.017.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceProstate Cancer Consensus ConferenceAdvanced prostate cancerProstate cancerClinical managementLack high-level evidenceConsensus conferenceManagement of patientsHigh-level evidenceEvidence-based guidelinesModified Delphi processCancer characteristicsClinical evidenceClinical trialsImpact daily practiceTreatment decisionsWeb-based surveyConsensus questionsPC expertsPatientsMeta-analysisCancerDelphi processDaily practicePanel membersCommission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection
Resio B, Tan K, Skovgard M, Dycoco J, Adusumilli P, Bains M, Bott M, Downey R, Gray K, Huang J, Molena D, Park B, Rusch V, Sihag S, Rocco G, Jones D, Isbell J. Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection. The Annals Of Thoracic Surgery 2024, 119: 308-315. PMID: 39299477, DOI: 10.1016/j.athoracsur.2024.09.009.Peer-Reviewed Original ResearchConceptsClinical stage IClinical stage III patientsStage III patientsStage IIII patientsLung resectionHilar lymph node stationsRate of nodal upstagingSystemic therapy administrationProspective institutional databaseLung cancer resectionLymph node stationsIn-hospital complicationsLymph node samplingLung cancer patientsDistant recurrenceNodal upstagingOncological outcomesPulmonary resectionOverall survivalCancer resectionDecrease recurrenceClinical stageII patientsImproved survivalTrends in Invasive Melanoma Thickness in Norway, 1983-2019.
Rimal R, Robsahm T, Green A, Ghiasvand R, Rueegg C, Bassarova A, Gjersvik P, Weiderpass E, Aalen O, Møller B, Perrier F, Veierød M. Trends in Invasive Melanoma Thickness in Norway, 1983-2019. Acta Dermato Venereologica 2024, 104: adv26110. PMID: 39221835, DOI: 10.2340/actadv.v104.26110.Peer-Reviewed Original ResearchConceptsLong-term incidence trendsCancer Registry of NorwayIncidence time trendsTumor thicknessCancer RegistryIncidence trendsBirth cohortTime trendsPrevention strategiesMelanoma occurrenceAge groupsMelanoma RegistryT categoryMelanoma thicknessT1 melanomasPathology reportsYounger patientsAnatomical sitesIncreased incidenceMelanomaSex differencesTumorIncidencePatientsMenSacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer.
Loriot Y, Balar A, Petrylak D, Kalebasty A, Grivas P, Fléchon A, Jain R, Swami U, Bupathi M, Barthélémy P, Beuzeboc P, Palmbos P, Kyriakopoulos C, Pouessel D, Sternberg C, Tonelli J, Sierecki M, Zavodovskaya M, Elboudwarej E, Diehl L, Jürgensmeier J, Tagawa S. Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer. Clinical Cancer Research 2024, 30: 3179-3188. PMID: 39086310, DOI: 10.1158/1078-0432.ccr-23-3924.Peer-Reviewed Original ResearchConceptsTrop-2 expressionTrop-2Positive tumor cellsUrothelial cancerMetastatic UCSacituzumab govitecanTumor cellsTumor samplesOpen-label phase II studyTrophoblast cell surface antigen 2Human trophoblast cell-surface antigen 2Advanced urothelial cancerSN-38 payloadPhase II studyC1-3Archival tumor samplesExpression levelsCohorts 1 to 3Surface antigen 2Antibody drug conjugatesOS benefitII studyExamined tumorsH-scoreMembrane expressionNCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.
Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Jones F, Gurski L. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: 366-375. PMID: 39151454, DOI: 10.6004/jnccn.2024.0041.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyHumansMedical OncologyNeoadjuvant TherapyNeoplasm StagingRectal NeoplasmsConceptsRectal cancerResponders to neoadjuvant therapyRisk of pelvic recurrenceLocally recurrent rectal cancerEarly-stage rectal cancerNonoperative management approachRecurrent rectal cancerDistal rectal cancerNCCN Guidelines InsightsCurative-intent therapyRectal cancer surgeryOptimal treatment planEndoscopic submucosal dissectionQuality of lifePelvic recurrenceNeoadjuvant therapyMultimodal therapyNCCN GuidelinesGenitourinary functionPatient selectionPoor prognosisCancer surgeryColon cancerSubmucosal dissectionClinical trialsNeuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Bagatell R, Park J, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai A, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang L. Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 413-433. PMID: 39151455, DOI: 10.6004/jnccn.2024.0040.Peer-Reviewed Original ResearchConceptsNCCN GuidelinesNCCN Clinical Practice GuidelinesClinically heterogeneous diseaseExtracranial solid tumorTreatment of neuroblastomaClinical practice guidelinesNeuroblastoma panelRadiation oncologistsNCCN Member InstitutionsSolid tumorsHeterogeneous diseaseConsensus recommendationsPediatric oncologistsNeuroblastomaNCCNGroup of representativesRisk classificationEvidence-basedMultidisciplinary groupPractice guidelinesOncologistsMember institutionsGuidelinesTreatmentTumorChart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart reviewAssociation of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer
Maduka R, Canavan M, Walters S, Ermer T, Zhan P, Kaminski M, Li A, Pichert M, Salazar M, Prsic E, Boffa D. Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer. Cancer Medicine 2024, 13: e7028. PMID: 38711364, PMCID: PMC11074703, DOI: 10.1002/cam4.7028.Peer-Reviewed Original ResearchConceptsOptimal quality of careQuality of carePatient socioeconomic statusAssociated with improved qualityAssociated with improved quality of lifeEnd-of-lifeUS cancer populationPalliative treatmentQuality of lifeCox proportional hazards modelsMultivariate logistic regressionInformed decision makingProportional hazards modelFacility characteristicsNon-HispanicAssociated with lower ratesInsurance payer statusImproving informed decision makingCancer populationSocioeconomic statusHispanic ethnicityTreatment usePayer statusBlack raceLogistic regressionShould the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
Woodard G, Dacic S. Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors? Journal Of Thoracic Oncology 2024, 19: 663-665. PMID: 38719420, DOI: 10.1016/j.jtho.2024.01.004.Peer-Reviewed Original ResearchTrends and predictors of Quality of Life in lung cancer survivors
Bade B, Zhao J, Li F, Tanoue L, Lazowski H, Alfano C, Silvestri G, Irwin M. Trends and predictors of Quality of Life in lung cancer survivors. Lung Cancer 2024, 191: 107793. PMID: 38640687, DOI: 10.1016/j.lungcan.2024.107793.Peer-Reviewed Original ResearchConceptsFunctional Assessment of Cancer Therapy - LungNon-small cell lung cancerHR-QOL scoresLung cancer survivorsHR-QOLAdvanced stage non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerQuality of lifeCancer survivorsPhysical activityCell lung cancerEarly-stage diseasePredictors of quality of lifeHealth-related quality of lifeFollow-upHealth-related qualityHealthy weight maintenancePerformance statusAdvanced-stage non-small cell lung cancerLung cancerClinical significanceAssociated with older ageDiagnosed NSCLCTreatment-related side effectsInfluence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
Contieri R, Tan W, Grajales V, Hensley P, Martini A, Bree K, Myers A, Nogueras‐Gonzalez G, Navai N, Dinney C, Guo C, Kamat A. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU International 2024, 133: 733-741. PMID: 38374533, DOI: 10.1111/bju.16293.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerImmediate radical cystectomyCancer-specific survivalMetastasis-free survivalProgression-free survivalT1 substagingOverall survivalRadical cystectomyPathology reportsBladder cancerHigh-grade non-muscle-invasive bladder cancerPatients treated with bacillus Calmette-GuerinAssociated with poor progression-free survivalInstitutional review board-approved retrospective studyPatients treated with BCGPoor progression-free survivalLamina propriaAssociated with upstagingBCG-treated patientsCalculate overall survivalTreated with BCGKaplan-Meier methodHigh-grade patientsMultivariate Cox modelInvasive characteristicsThe artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma
Pan X, AbdulJabbar K, Coelho-Lima J, Grapa A, Zhang H, Cheung A, Baena J, Karasaki T, Wilson C, Sereno M, Veeriah S, Aitken S, Hackshaw A, Nicholson A, Jamal-Hanjani M, Swanton C, Yuan Y, Le Quesne J, Moore D. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma. Nature Cancer 2024, 5: 347-363. PMID: 38200244, PMCID: PMC10899116, DOI: 10.1038/s43018-023-00694-w.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungArtificial IntelligenceHumansLung NeoplasmsNeoplasm Staging
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply